Literature DB >> 21954677

Screening for colorectal cancer.

Jin He1, Jonathan E Efron.   

Abstract

March is national colorectal cancer awareness month. It is estimated that as many as 60% of colorectal cancer deaths could be prevented if all men and women aged 50 years or older were screened routinely. In 2000, Katie Couric's televised colonoscopy led to a 20% increase in screening colonoscopies across America, a stunning rise called the "Katie Couric Effect". This event demonstrated how celebrity endorsement affects health behavior. Currently, discussion is ongoing about the optimal strategy for CRC screening, particularly the costs of screening colonoscopy. The current CRC screening guidelines are summarized in Table 2. Debates over the optimum CRC screening test continue in the face of evidence that 22 million Americans aged 50 to 75 years are not screened for CRC by any modality and 25,000 of those lives may have been saved if they had been screened for CRC. It is clear that improving screening rates and reducing disparities in underscreened communities and population subgroups could further reduce colorectal cancer morbidity and mortality. National Institutes of Health consensus identified the following priority areas to enhance the use and quality of colorectal cancer screening: Eliminate financial barriers to colorectal cancer screening and appropriate follow-up of positive results of colorectal cancer screening. Develop systems to ensure the high quality of colorectal cancer screening programs. Conduct studies to determine the comparative effectiveness of the various colorectal cancer screening methods in usual practice settings. Encouraging population adherence to screening tests and allowing patients to select the tests they prefer may do more good (as long as they choose something) than whatever procedure is chosen by the medical profession as the preferred test.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21954677     DOI: 10.1016/j.yasu.2011.03.006

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  12 in total

1.  Genetic mutations in human rectal cancers detected by targeted sequencing.

Authors:  Jun Bai; Jinglong Gao; Zhijun Mao; Jianhua Wang; Jianhui Li; Wensheng Li; Yu Lei; Shuaishuai Li; Zhuo Wu; Chuanning Tang; Lindsey Jones; Hua Ye; Feng Lou; Zhiyuan Liu; Zhishou Dong; Baishuai Guo; Xue F Huang; Si-Yi Chen; Enke Zhang
Journal:  J Hum Genet       Date:  2015-07-02       Impact factor: 3.172

2.  iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer.

Authors:  Yiming Ma; Ting Xiao; Quan Xu; Xinxin Shao; Hongying Wang
Journal:  Front Med       Date:  2016-06-09       Impact factor: 4.592

3.  MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4.

Authors:  Liang-Pan Shi; Hai-Lian Guo; Yi-Bin Su; Zhi-Hua Zheng; Jiang-Rui Liu; Shu-Hua Lai
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 4.  Clinical implications of microRNAs in cancer.

Authors:  L C Bovell; B D K Putcha; T Samuel; U Manne
Journal:  Biotech Histochem       Date:  2013-05-07       Impact factor: 1.718

5.  Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial.

Authors:  Per J Nilsson; Boudewijn van Etten; Geke A P Hospers; Lars Påhlman; Cornelis J H van de Velde; Regina G H Beets-Tan; Lennart Blomqvist; Jannet C Beukema; Ellen Kapiteijn; Corrie A M Marijnen; Iris D Nagtegaal; Theo Wiggers; Bengt Glimelius
Journal:  BMC Cancer       Date:  2013-06-07       Impact factor: 4.430

6.  Blood-based protein biomarker panel for the detection of colorectal cancer.

Authors:  Kim Y C Fung; Bruce Tabor; Michael J Buckley; Ilka K Priebe; Leanne Purins; Celine Pompeia; Gemma V Brierley; Trevor Lockett; Peter Gibbs; Jeanne Tie; Paul McMurrick; James Moore; Andrew Ruszkiewicz; Edouard Nice; Timothy E Adams; Antony Burgess; Leah J Cosgrove
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  Blood-Based Protein Signatures for Early Detection of Colorectal Cancer: A Systematic Review.

Authors:  Megha Bhardwaj; Anton Gies; Simone Werner; Petra Schrotz-King; Hermann Brenner
Journal:  Clin Transl Gastroenterol       Date:  2017-11-30       Impact factor: 4.488

8.  Evaluation of the analytical performance of the novel NS-Prime system and examination of temperature stability of fecal transferrin compared with fecal hemoglobin as biomarkers in a colon cancer screening program.

Authors:  Wael L L Demian; Stacy Collins; Candace Fowler; Jerry McGrath; Scott Antle; Zoë Moores; Deborah Hollohan; Suzanne Lacey; Joseph Banoub; Edward Randell
Journal:  Pract Lab Med       Date:  2015-07-22

9.  Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.

Authors:  Shu-Chen Wei; Po-Nien Tsao; Yu-Ting Wang; Been-Ren Lin; Deng-Chyang Wu; Wen-Sy Tsai; Jinn-Shiun Chen; Jau-Min Wong
Journal:  Cancer Med       Date:  2019-05-07       Impact factor: 4.452

10.  Targeted therapies in colorectal cancer-an integrative view by PPPM.

Authors:  Suzanne Hagan; Maria C M Orr; Brendan Doyle
Journal:  EPMA J       Date:  2013-01-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.